Methocarbamol DC Granules are pharmaceutical formulation granules containing Methocarbamol in a controlled granular format intended for direct-compression applications. Methocarbamol is a centrally acting skeletal muscle relaxant used in oral pharmaceutical formulations. The USP-NF monograph identifies Methocarbamol with the molecular formula C11H15NO5, molecular weight 241.24 g/mol, and CAS Number 532-03-6. The USP definition specifies 98.5% to 101.5% Methocarbamol, calculated on the dried basis.
The DC designation refers to Direct Compression. Direct compression is a tablet manufacturing approach in which an appropriately engineered formulation blend is compressed directly into tablets. Successful direct-compression processing depends on material properties such as flowability, particle-size distribution, density, compressibility, compactability and blend uniformity. Pharmaceutical research identifies flow and compactability as important factors affecting direct-compression performance.
Methocarbamol DC Granules are a granulated pharmaceutical formulation containing Methocarbamol together with selected excipients designed to provide suitable physical characteristics for compression-based manufacturing.
The finished granules are different from the Methocarbamol API itself because they represent a complete formulation system. Their characteristics depend on the API properties, excipient composition, granulation or particle-engineering process, particle-size distribution, moisture level and manufacturing conditions.
A properly characterized granular formulation can support controlled handling, blending and compression during pharmaceutical manufacturing.
Methocarbamol has the chemical formula C11H15NO5 and molecular weight 241.24 g/mol. The USP-NF monograph identifies Methocarbamol under CAS Number 532-03-6 and specifies an assay range of 98.5% to 101.5% calculated on the dried basis for the API substance.
For finished Methocarbamol DC Granules, the API assay should be established using the validated analytical method and approved finished-product specification. The API monograph value should not automatically be copied as the finished granule assay unless the finished-product specification uses the same analytical basis.
Direct compression is used to simplify tablet manufacturing by allowing a suitable formulation blend to be compressed without a conventional wet-granulation operation.
For Methocarbamol DC Granules, the finished granular material should possess physical characteristics appropriate for feeding, blending and compression. Research into direct-compression technology emphasizes the relationship between raw-material properties and final tablet quality.
Important characteristics may include:
The actual acceptance criteria should be established from the approved product specification.
Particle-size distribution is an important quality attribute for Methocarbamol DC Granules because particle size can influence material flow, packing, blending and compression behavior.
The finished granules can be characterized using D10, D50 and D90 measurements when these parameters are part of the approved specification.
A controlled particle-size distribution can support consistent material handling and processing. However, numerical particle-size limits should be based on actual manufacturing and analytical data rather than assigned as universal values.
Consistent flow is important during pharmaceutical manufacturing because the formulation must move through processing equipment and fill compression dies consistently.
Methocarbamol DC Granules may be evaluated using:
These measurements can help characterize the physical handling properties of the finished granules.
Scientific literature on direct-compression excipients emphasizes the importance of optimizing both powder flow and compactability for reliable tablet manufacture.
Compressibility and compactability are key considerations for a formulation intended for direct compression.
Compressibility describes how a powder or granular material responds to applied pressure, while compactability describes its ability to form a mechanically strong compact.
During development of Methocarbamol DC Granules, formulation developers may evaluate:
These parameters are formulation- and process-dependent and should not be presented as universal specifications for every Methocarbamol DC Granules grade.
Content uniformity is an important consideration for finished granules containing an active pharmaceutical ingredient. Consistent distribution of Methocarbamol throughout the formulation supports reproducible dosage-unit manufacturing.
Particle engineering has been investigated as a method for improving content uniformity in low-dose direct-compression formulations. Research has shown that engineered API-carrier particles can improve powder flow, tabletability and content uniformity across different active ingredients.
For Methocarbamol DC Granules, the appropriate sampling strategy and acceptance criteria should be established using validated manufacturing and analytical procedures.
The dissolution behavior of Methocarbamol formulations depends on the API characteristics, particle size, excipient selection, granule structure, compression conditions and final formulation design.
The finished granules may therefore be evaluated during formulation development for dissolution performance.
Specific dissolution percentages and time points should not be presented as universal values unless supported by the validated finished-product method and approved specification.
Moisture content can influence the physical characteristics of pharmaceutical granules, including flow, packing and compression behavior.
For Methocarbamol DC Granules, moisture should be monitored according to the approved product specification and stability requirements.
Packaging and storage conditions should be established according to validated stability data for the finished formulation.
Methocarbamol DC Granules may be evaluated for oral solid dosage formulations requiring a controlled granular format for direct-compression processing.
Potential applications include:
The final formulation composition and processing conditions should be established through formulation development and validation.
Quality control for Methocarbamol DC Granules should address chemical identity, assay, purity and physical processing characteristics.
Potential quality attributes include:
USP-NF specifies Methocarbamol at 98.5% to 101.5% on the dried basis for the API substance.
This API requirement should be distinguished from the finished-product specification for Methocarbamol DC Granules.
Development of Methocarbamol DC Granules can involve evaluation of both the API and excipient system.
Important development studies may include:
A systematic approach to direct-compression development can help identify the material attributes and process parameters that influence final tablet quality.
Methocarbamol DC Granules may be considered for:
The final application should be established using product-specific formulation and performance data.
| Parameter | Specification |
|---|---|
| Appearance | White to off-white granules |
| Identification | IR & HPLC compliant |
| Assay (HPLC) | 98.0% – 102.0% |
| Loss on Drying | NMT 1.0% |
| Residue on Ignition | NMT 0.1% |
| Heavy Metals | NMT 10 ppm |
| Water Content | NMT 1.0% |